Senti Biosciences Statistics
Share Statistics
Senti Biosciences has 25.99M
shares outstanding. The number of shares has increased by -43.21%
in one year.
| Shares Outstanding | 25.99M |
| Shares Change (YoY) | -43.21% |
| Shares Change (QoQ) | 466.31% |
| Owned by Institutions (%) | 5.54% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 617 |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 69.45K, so 0.27% of the outstanding
shares have been sold short.
| Short Interest | 69.45K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.28% |
| Short Ratio (days to cover) | 3.12 |
Valuation Ratios
The PE ratio is -0.31 and the forward
PE ratio is -0.58.
Senti Biosciences's PEG ratio is
0.01.
| PE Ratio | -0.31 |
| Forward PE | -0.58 |
| PS Ratio | 0 |
| Forward PS | 22.8 |
| PB Ratio | 0.63 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Senti Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.49,
with a Debt / Equity ratio of 1.31.
| Current Ratio | 4.49 |
| Quick Ratio | 4.49 |
| Debt / Equity | 1.31 |
| Debt / EBITDA | -0.55 |
| Debt / FCF | -0.81 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,552,647.06 |
| Employee Count | 34 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -9.49% in the
last 52 weeks. The beta is 2.33, so Senti Biosciences's
price volatility has been higher than the market average.
| Beta | 2.33 |
| 52-Week Price Change | -9.49% |
| 50-Day Moving Average | 3.52 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 43.91 |
| Average Volume (20 Days) | 95,467 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -61.04M |
| Net Income | -52.79M |
| EBITDA | -61.04M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -11.49 |
Full Income StatementBalance Sheet
The company has 48.28M in cash and 33.54M in
debt, giving a net cash position of 14.74M.
| Cash & Cash Equivalents | 48.28M |
| Total Debt | 33.54M |
| Net Cash | 14.74M |
| Retained Earnings | -297.13M |
| Total Assets | 97.84M |
| Working Capital | 45.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -41.4M
and capital expenditures -26K, giving a free cash flow of -41.42M.
| Operating Cash Flow | -41.4M |
| Capital Expenditures | -26K |
| Free Cash Flow | -41.42M |
| FCF Per Share | -9.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
